JP2023545508A - Ｉｋｚｆ２又はｉｋｚｆ４を分解する三環式リガンド - Google Patents

Ｉｋｚｆ２又はｉｋｚｆ４を分解する三環式リガンド Download PDF

Info

Publication number
JP2023545508A
JP2023545508A JP2023523007A JP2023523007A JP2023545508A JP 2023545508 A JP2023545508 A JP 2023545508A JP 2023523007 A JP2023523007 A JP 2023523007A JP 2023523007 A JP2023523007 A JP 2023523007A JP 2023545508 A JP2023545508 A JP 2023545508A
Authority
JP
Japan
Prior art keywords
compound according
certain embodiments
compound
cancer
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023523007A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022081925A5 (https=
JP2023545508A5 (https=
Inventor
クリストファー ジー． ナスヴェシュク
ジェームズ エー． ヘンダーソン
モーゼ ムースタキム
アンドリュー チャールズ グッド
デイビッド プロイア
Original Assignee
シーフォー セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シーフォー セラピューティクス， インコーポレイテッド filed Critical シーフォー セラピューティクス， インコーポレイテッド
Publication of JP2023545508A publication Critical patent/JP2023545508A/ja
Publication of JPWO2022081925A5 publication Critical patent/JPWO2022081925A5/ja
Publication of JP2023545508A5 publication Critical patent/JP2023545508A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
JP2023523007A 2020-10-14 2021-10-14 Ｉｋｚｆ２又はｉｋｚｆ４を分解する三環式リガンド Pending JP2023545508A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063091875P 2020-10-14 2020-10-14
US63/091,875 2020-10-14
PCT/US2021/055102 WO2022081925A1 (en) 2020-10-14 2021-10-14 Tricyclic ligands for degradation of ikzf2 or ikzf4

Publications (3)

Publication Number Publication Date
JP2023545508A true JP2023545508A (ja) 2023-10-30
JPWO2022081925A5 JPWO2022081925A5 (https=) 2024-10-22
JP2023545508A5 JP2023545508A5 (https=) 2024-10-22

Family

ID=81208646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023523007A Pending JP2023545508A (ja) 2020-10-14 2021-10-14 Ｉｋｚｆ２又はｉｋｚｆ４を分解する三環式リガンド

Country Status (10)

Country Link
US (1) US20230339902A1 (https=)
EP (1) EP4228639A4 (https=)
JP (1) JP2023545508A (https=)
KR (1) KR20230107569A (https=)
CN (1) CN116783180A (https=)
AU (1) AU2021361043A1 (https=)
CA (1) CA3194169A1 (https=)
IL (1) IL302038A (https=)
MX (1) MX2023004374A (https=)
WO (1) WO2022081925A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023545509A (ja) * 2020-10-14 2023-10-30 シーフォー セラピューティクス， インコーポレイテッド 医学的療法のための、ネオ基質を分解する三環式化合物

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4717317A2 (en) 2017-06-20 2026-04-01 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
CN118201923A (zh) * 2021-10-15 2024-06-14 海南先声再明医药股份有限公司 三环类化合物
EP4540241A1 (en) * 2022-06-16 2025-04-23 Monte Rosa Therapeutics AG Substituted piperidines as ck1a degraders
WO2024073507A1 (en) 2022-09-28 2024-04-04 Theseus Pharmaceuticals, Inc. Macrocyclic compounds and uses thereof
CN116655595A (zh) * 2023-06-05 2023-08-29 中国人民解放军军事科学院军事医学研究院 2,6-哌啶二酮衍生物及其制备和用途
WO2025006753A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein
WO2025006783A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras
WO2025097092A1 (en) * 2023-11-02 2025-05-08 Neomorph, Inc. Substituted 3-(5-(4-hydroxypiperidin-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and 3-(2-(4-hydroxypiperidin-4-yl)-5-oxo-5,7-dihydro-6h-pyrrolo[3,4-b]pyridin-6-yl)piperidine-2,6-dione derivatives and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025162410A1 (zh) * 2024-01-31 2025-08-07 微境生物医药科技(上海)有限公司 新型蛋白降解剂及抗体-蛋白降解剂偶联物

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019038717A1 (en) * 2017-08-23 2019-02-28 Novartis Ag 3- (1-OXOISOINDOLIN-2-YL) PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
WO2020012334A1 (en) * 2018-07-10 2020-01-16 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
WO2020012337A1 (en) * 2018-07-10 2020-01-16 Novartis Ag 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases
WO2020165834A1 (en) * 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020165833A1 (en) * 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP2023538520A (ja) * 2020-08-07 2023-09-08 シーフォー セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓ又はａｉｏｌｏｓによって媒介される障害に対する有利な治療法
JP2023545509A (ja) * 2020-10-14 2023-10-30 シーフォー セラピューティクス， インコーポレイテッド 医学的療法のための、ネオ基質を分解する三環式化合物
JP2023545507A (ja) * 2020-10-14 2023-10-30 シーフォー セラピューティクス， インコーポレイテッド 標的化タンパク質を分解する三環式ヘテロ二官能性化合物
JP7692362B2 (ja) * 2019-04-12 2025-06-13 シーフォー セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓ及びＡｉｏｌｏｓの三環式分解誘導薬

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6504034B2 (en) * 2001-01-23 2003-01-07 Hoffmann-La Roche Inc. Naphthostyrils
CN105985282B (zh) * 2015-01-28 2020-12-08 中国科学院广州生物医药与健康研究院 一种2-氧代-1,2-二氢苯并[cd]吲哚类化合物及其应用
US11220515B2 (en) * 2018-01-26 2022-01-11 Yale University Imide-based modulators of proteolysis and associated methods of use
EP3813834B1 (en) * 2018-06-29 2025-03-26 Dana-Farber Cancer Institute, Inc. New crbn modulators
KR20210106437A (ko) * 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
WO2020243379A1 (en) * 2019-05-31 2020-12-03 Celgene Corporation Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith
US20240383886A1 (en) * 2019-12-20 2024-11-21 Calico Life Sciences Llc Protein Tyrosine Phosphatase Degraders and Methods of Use Thereof
TW202140441A (zh) * 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019038717A1 (en) * 2017-08-23 2019-02-28 Novartis Ag 3- (1-OXOISOINDOLIN-2-YL) PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
WO2020012334A1 (en) * 2018-07-10 2020-01-16 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
WO2020012337A1 (en) * 2018-07-10 2020-01-16 Novartis Ag 3-(5-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of i karos family zinc finger 2 (ikzf2)-dependent diseases
WO2020165834A1 (en) * 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020165833A1 (en) * 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP7692362B2 (ja) * 2019-04-12 2025-06-13 シーフォー セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓ及びＡｉｏｌｏｓの三環式分解誘導薬
JP2023538520A (ja) * 2020-08-07 2023-09-08 シーフォー セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓ又はａｉｏｌｏｓによって媒介される障害に対する有利な治療法
JP2023545509A (ja) * 2020-10-14 2023-10-30 シーフォー セラピューティクス， インコーポレイテッド 医学的療法のための、ネオ基質を分解する三環式化合物
JP2023545507A (ja) * 2020-10-14 2023-10-30 シーフォー セラピューティクス， インコーポレイテッド 標的化タンパク質を分解する三環式ヘテロ二官能性化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023545509A (ja) * 2020-10-14 2023-10-30 シーフォー セラピューティクス， インコーポレイテッド 医学的療法のための、ネオ基質を分解する三環式化合物

Also Published As

Publication number Publication date
AU2021361043A1 (en) 2023-06-08
EP4228639A1 (en) 2023-08-23
CN116783180A (zh) 2023-09-19
MX2023004374A (es) 2023-07-06
CA3194169A1 (en) 2022-04-21
WO2022081925A1 (en) 2022-04-21
KR20230107569A (ko) 2023-07-17
AU2021361043A9 (en) 2025-03-13
US20230339902A1 (en) 2023-10-26
IL302038A (en) 2023-06-01
EP4228639A4 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
US20230339902A1 (en) Tricyclic ligands for degradation of ikzf2 or ikzf4
US20240018118A1 (en) Tricyclic compounds to degrade neosubstrates for medical therapy
JP7846819B2 (ja) Ｉｋａｒｏｓ及びＡｉｏｌｏｓの三環式分解誘導薬
US12157735B2 (en) Compounds for targeted degradation of BRD9
IL302037A (en) Tricyclic heterobifunctional compounds for degradation of targeted proteins
RU2833608C2 (ru) Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241011

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250909

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260402